AKBA
AKBA
NASDAQ · Biotechnology

Akebia Therapeutics Inc

$1.41
+0.05 (+3.68%)
Analyst Consensus
Strong Buy
11
Analysts
Moderate
Coverage
Buy 10 91%
Hold 1 9%
Sell 0 0%
Price Target
Analyst Price Target +2,556.0% upside
Low Target $22.27
Average Target $37.45
High Target $46.32
Current Price $1.41
Current
$1.41
Target
$37.45
$22.27 $37.45 avg $46.32
Scenario Analysis
Bear Case
$22.27
1,479.4%
Low target
Base Case
$37.45
+2,556.0%
Avg target
Bull Case
$46.32
+3,185.1%
High target
Risk/Reward
2.2x
Favorable
Price in Context
52-Week High
$4.08
-65.4% from high
52-Week Low
$1.14
+23.7% from low
Target vs 52W High
$37.45
+818.2% vs high
Peer Consensus — Biotechnology
Stock Consensus Analysts Buy % Target Upside
ABBV
Abbvie Inc
Buy 39 69% $257.58 +24.3%
AMGN
Amgen Inc
Hold 42 50% $190.87 -46.1%
GILD
Gilead Sciences Inc
Strong Buy 37 81% $362.68 +162.3%
VRTX
Vertex Pharmaceuticals Inc
Strong Buy 39 79% $438.34 -3.7%
REGN
Regeneron Pharmaceuticals
Strong Buy 36 75% $76.80 -89.8%
ALNY
Alnylam Pharmaceuticals Inc
Strong Buy 36 78% $102.31 -68.9%
INSM
Insmed Inc
Strong Buy 26 92% $143.40 -3.3%
NTRA
Natera Inc
Strong Buy 27 89% $142.91 -27.6%